{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T05:28:22Z","timestamp":1774589302811,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T00:00:00Z","timestamp":1565740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"National Institute of Health","award":["DK093848"],"award-info":[{"award-number":["DK093848"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00125-019-4963-5","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T04:48:44Z","timestamp":1565758124000},"page":"1928-1937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6564-6142","authenticated-orcid":false,"given":"Chelsea R.","family":"Hutch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Roelofs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Sorrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Leix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David D.","family":"D\u2019Alessio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy J.","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darleen A.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,14]]},"reference":[{"issue":"11","key":"4963_CR1","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1002\/oby.21629","volume":"24","author":"K Fujioka","year":"2016","unstructured":"Fujioka K, O\u2019Neil PM, Davies M et al (2016) Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity 24(11):2278\u20132288. \n                    https:\/\/doi.org\/10.1002\/oby.21629","journal-title":"Obesity"},{"issue":"8","key":"4963_CR2","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.2337\/db16-0107","volume":"65","author":"MA Nauck","year":"2016","unstructured":"Nauck MA, Kind J, K\u00f6the LDLD et al (2016) Quantification of the contribution of GLP-1 to mediating insulinotropic effects of DPP-4 inhibition with vildagliptin in healthy subjects and patients with type 2 diabetes using exendin [9-39] as a GLP-1 receptor antagonist. Diabetes 65(8):2440\u20132447. \n                    https:\/\/doi.org\/10.2337\/db16-0107","journal-title":"Diabetes"},{"issue":"3","key":"4963_CR3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","volume":"53","author":"JJ Meier","year":"2004","unstructured":"Meier JJ, Nauck MA, Kranz D et al (2004) Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53(3):654\u2013662. \n                    https:\/\/doi.org\/10.2337\/diabetes.53.3.654","journal-title":"Diabetes"},{"issue":"3","key":"4963_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.regpep.2006.07.007","volume":"137","author":"T Vilsb\u00f8ll","year":"2006","unstructured":"Vilsb\u00f8ll T, Agers\u00f8 H, Lauritsen T et al (2006) The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects. Regul Pept 137(3):168\u2013172. \n                    https:\/\/doi.org\/10.1016\/j.regpep.2006.07.007","journal-title":"Regul Pept"},{"issue":"5","key":"4963_CR5","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1172\/JCI43615","volume":"121","author":"S Ali","year":"2011","unstructured":"Ali S, Lamont BJ, Charron MJ, Drucker DJ (2011) Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 121(5):1917\u20131929. \n                    https:\/\/doi.org\/10.1172\/JCI43615","journal-title":"J Clin Invest"},{"issue":"8","key":"4963_CR6","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00125-002-0878-6","volume":"45","author":"T Vilsb\u00f8ll","year":"2002","unstructured":"Vilsb\u00f8ll T, Krarup T, Madsbad S, Holst JJ (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45(8):1111\u20131119. \n                    https:\/\/doi.org\/10.1007\/s00125-002-0878-6","journal-title":"Diabetologia"},{"issue":"1","key":"4963_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","volume":"91","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Heimesaat MM, Orskov C et al (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301\u2013307. \n                    https:\/\/doi.org\/10.1172\/JCI116186","journal-title":"J Clin Invest"},{"issue":"1-2","key":"4963_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","volume":"1","author":"Y Seino","year":"2010","unstructured":"Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 1(1-2):8\u201323. \n                    https:\/\/doi.org\/10.1111\/j.2040-1124.2010.00022.x","journal-title":"J Diabetes Invest"},{"issue":"4","key":"4963_CR9","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cmet.2017.02.008","volume":"25","author":"AP Chambers","year":"2017","unstructured":"Chambers AP, Sorrell JE, Haller A et al (2017) The role of pancreatic preproglucagon in glucose homeostasis in mice. Cell Metab 25(4):927\u2013934. \n                    https:\/\/doi.org\/10.1016\/j.cmet.2017.02.008","journal-title":"Cell Metab"},{"issue":"27","key":"4963_CR10","doi-asserted-by":"publisher","first-page":"19760","DOI":"10.1074\/jbc.M112.426288","volume":"288","author":"P Ravn","year":"2013","unstructured":"Ravn P, Madhurantakam C, Kunze S et al (2013) Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 288(27):19760\u201319772. \n                    https:\/\/doi.org\/10.1074\/jbc.M112.426288","journal-title":"J Biol Chem"},{"issue":"1","key":"4963_CR11","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1124\/jpet.107.135723","volume":"325","author":"L Thomas","year":"2008","unstructured":"Thomas L, Eckhardt M, Langkopf E et al (2008) (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325(1):175\u2013182. \n                    https:\/\/doi.org\/10.1124\/jpet.107.135723","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4963_CR12","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2337\/db12-0294","volume":"62","author":"A Fukami","year":"2013","unstructured":"Fukami A, Seino Y, Ozaki N et al (2013) Ectopic expression of GIP in pancreatic \u03b2-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 62(2):510\u2013518. \n                    https:\/\/doi.org\/10.2337\/db12-0294","journal-title":"Diabetes"},{"issue":"1","key":"4963_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jdi.12718","volume":"9","author":"D Yabe","year":"2018","unstructured":"Yabe D, Seino Y, Seino Y (2018) Incretin concept revised: the origin of the insulinotropic function of glucagon-like peptide-1: the gut, the islets or both? J Diabetes Investig 9(1):21\u201324. \n                    https:\/\/doi.org\/10.1111\/jdi.12718","journal-title":"J Diabetes Investig"},{"issue":"4","key":"4963_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bbrc.2007.08.115","volume":"362","author":"S Piteau","year":"2007","unstructured":"Piteau S, Olver A, Kim S-J et al (2007) Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker rat. Biochem Biophys Res Commun 362(4):1007\u20131012. \n                    https:\/\/doi.org\/10.1016\/j.bbrc.2007.08.115","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"4963_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2337\/diabetes.53.5.1326","volume":"53","author":"T Hansotia","year":"2004","unstructured":"Hansotia T, Baggio LL, Delmeire D et al (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53(5):1326\u20131335. \n                    https:\/\/doi.org\/10.2337\/diabetes.53.5.1326","journal-title":"Diabetes"},{"issue":"12","key":"4963_CR16","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.2337\/db07-0697","volume":"56","author":"G Flock","year":"2007","unstructured":"Flock G, Baggio LL, Longuet C, Drucker DJ (2007) Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56(12):3006\u20133013. \n                    https:\/\/doi.org\/10.2337\/db07-0697","journal-title":"Diabetes"},{"issue":"6","key":"4963_CR17","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","volume":"35","author":"EE Mulvihill","year":"2014","unstructured":"Mulvihill EE, Drucker DJ (2014) Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35(6):992\u20131019. \n                    https:\/\/doi.org\/10.1210\/er.2014-1035","journal-title":"Endocr Rev"},{"issue":"3","key":"4963_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2337\/db13-1455","volume":"63","author":"BA Aulinger","year":"2014","unstructured":"Aulinger BA, Bedorf A, Kutscherauer G et al (2014) Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade. Diabetes 63(3):1079\u20131092. \n                    https:\/\/doi.org\/10.2337\/db13-1455","journal-title":"Diabetes"},{"issue":"1","key":"4963_CR19","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.cmet.2016.10.007","volume":"25","author":"EE Mulvihill","year":"2017","unstructured":"Mulvihill EE, Varin EM, Gladanac B et al (2017) Cellular sites and mechanisms linking reduction of dipeptidyl peptidase-4 activity to control of incretin hormone action and glucose homeostasis. Cell Metab 25(1):152\u2013165. \n                    https:\/\/doi.org\/10.1016\/j.cmet.2016.10.007","journal-title":"Cell Metab"},{"issue":"8","key":"4963_CR20","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1210\/en.2011-0286","volume":"152","author":"A Waget","year":"2011","unstructured":"Waget A, Cabou C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152(8):3018\u20133029. \n                    https:\/\/doi.org\/10.1210\/en.2011-0286","journal-title":"Endocrinology"},{"issue":"8","key":"4963_CR21","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1007\/s00125-017-4303-6","volume":"60","author":"D Kawamori","year":"2017","unstructured":"Kawamori D, Shirakawa J, Liew CW et al (2017) GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in \u03b2IRKO mice. Diabetologia 60(8):1442\u20131453. \n                    https:\/\/doi.org\/10.1007\/s00125-017-4303-6","journal-title":"Diabetologia"},{"issue":"12","key":"4963_CR22","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1007\/s00125-012-2716-9","volume":"55","author":"P Marchetti","year":"2012","unstructured":"Marchetti P, Lupi R, Bugliani M et al (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55(12):3262\u20133272. \n                    https:\/\/doi.org\/10.1007\/s00125-012-2716-9","journal-title":"Diabetologia"},{"issue":"13","key":"4963_CR23","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1016\/j.celrep.2017.03.005","volume":"18","author":"S Traub","year":"2017","unstructured":"Traub S, Meier DT, Schulze F et al (2017) Pancreatic \u03b1 cell-derived glucagon-related peptides are required for \u03b2 cell adaptation and glucose homeostasis. Cell Rep 18(13):3192\u20133203. \n                    https:\/\/doi.org\/10.1016\/j.celrep.2017.03.005","journal-title":"Cell Rep"},{"key":"4963_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.molmet.2018.02.008","volume":"11","author":"HV Lin","year":"2018","unstructured":"Lin HV, Wang J, Wang J et al (2018) GPR142 prompts glucagon-like peptide-1 release from islets to improve \u03b2 cell function. Mol Metab 11:205\u2013211. \n                    https:\/\/doi.org\/10.1016\/j.molmet.2018.02.008","journal-title":"Mol Metab"},{"issue":"5","key":"4963_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126742","volume":"4","author":"ME Capozzi","year":"2019","unstructured":"Capozzi ME, Svendsen B, Encisco SE et al (2019) \u03b2 Cell tone is defined by proglucagon peptides through cAMP signaling. JCI Insight 4(5):e126742. \n                    https:\/\/doi.org\/10.1172\/jci.insight.126742","journal-title":"JCI Insight"},{"issue":"1-2","key":"4963_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.mce.2011.04.008","volume":"339","author":"C Dorrell","year":"2011","unstructured":"Dorrell C, Grompe MT, Pan FC et al (2011) Isolation of mouse pancreatic alpha, beta, duct and acinar populations with cell surface markers. Mol Cell Endocrinol 339(1-2):144\u2013150. \n                    https:\/\/doi.org\/10.1016\/j.mce.2011.04.008","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"4963_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/41.1.8093256","volume":"41","author":"MD Poulsen","year":"1993","unstructured":"Poulsen MD, Hansen GH, Dabelsteen E et al (1993) Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J Histochem Cytochem 41(1):81\u201388. \n                    https:\/\/doi.org\/10.1177\/41.1.8093256","journal-title":"J Histochem Cytochem"},{"issue":"3","key":"4963_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.diabres.2015.10.010","volume":"110","author":"P Augstein","year":"2015","unstructured":"Augstein P, Naselli G, Loudovaris T et al (2015) Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells. Diabetes Res Clin Pract 110(3):291\u2013300. \n                    https:\/\/doi.org\/10.1016\/j.diabres.2015.10.010","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"4963_CR29","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1007\/s00125-014-3299-4","volume":"57","author":"BA Omar","year":"2014","unstructured":"Omar BA, Liehua L, Yamada Y et al (2014) Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57(9):1876\u20131883. \n                    https:\/\/doi.org\/10.1007\/s00125-014-3299-4","journal-title":"Diabetologia"},{"issue":"7","key":"4963_CR30","doi-asserted-by":"publisher","first-page":"E1163","DOI":"10.1210\/jc.2013-1029","volume":"98","author":"P Shah","year":"2013","unstructured":"Shah P, Ardestani A, Dharmadhikari G et al (2013) The DPP-4 inhibitor linagliptin restores \u03b2-cell function and survival in human isolated islets through GLP-1 stabilization. J Clin Endocrinol Metab 98(7):E1163\u2013E1172. \n                    https:\/\/doi.org\/10.1210\/jc.2013-1029","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"4963_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1530\/JOE-11-0094","volume":"211","author":"NM Whalley","year":"2011","unstructured":"Whalley NM, Pritchard LE, Smith DM, White A (2011) Processing of proglucagon to GLP-1 in pancreatic \u03b1-cells: is this a paracrine mechanism enabling GLP-1 to act on \u03b2-cells? J Endocrinol 211(1):99\u2013106. \n                    https:\/\/doi.org\/10.1530\/JOE-11-0094","journal-title":"J Endocrinol"},{"issue":"2","key":"4963_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1210\/jc.2008-1731","volume":"94","author":"K Aaboe","year":"2009","unstructured":"Aaboe K, Knop FK, Vilsboll T et al (2009) KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. J Clin Endocrinol Metab 94(2):603\u2013608. \n                    https:\/\/doi.org\/10.1210\/jc.2008-1731","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"4963_CR33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","volume":"52","author":"PV H\u00f8jberg","year":"2009","unstructured":"H\u00f8jberg PV, Vilsb\u00f8ll T, Rab\u00f8l R et al (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52(2):199\u2013207. \n                    https:\/\/doi.org\/10.1007\/s00125-008-1195-5","journal-title":"Diabetologia"},{"issue":"10160","key":"4963_CR34","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","volume":"392","author":"JP Frias","year":"2018","unstructured":"Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392(10160):2180\u20132193. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)32260-8","journal-title":"Lancet"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4963-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T23:20:22Z","timestamp":1597360822000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4963"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4963-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RJS has received research support from Ethicon Endo-Surgery, Novo Nordisk, Sanofi and Janssen. RJS has served on scientific advisory boards for Ethicon Endo-Surgery, Daiichi Sankyo, Janssen, Novartis, Nestle, Takeda, Boehringer Ingelheim, Sanofi and Novo Nordisk and is a paid speaker for Ethicon Endo-Surgery. DAS has received research support from Ethicon Endo-Surgery, Novo Nordisk and Boehringer Ingelheim. All other authors declare no duality of interest associated with this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}